TP53 and head and neck squamous cell carcinoma: Driehuis et al. validated the utility of 31 patient-derived HNSCC organoids—recapitulating genetic and molecular traits of primary tumors (e.g., 69% TP53 mutation rate)—in drug sensitivity testing for HNSCC.